Navigation Links
Micromet's BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkin's Lymphoma
Date:6/5/2008

ma. MT110, which is targeting EpCAM (CD326) and is the first BiTE antibody with potential applications in the treatment of solid tumors, is in a phase 1 clinical trial in patients with lung or gastrointestinal cancers. Two additional BiTE antibodies, targeting CD33 and MCSP, are in preclinical development.

About Micromet, Inc.

Micromet, Inc. (http://www.micromet-inc.com) is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Four of its antibodies are currently in clinical trials, while the remainder of the product pipeline is in preclinical development. The BiTE(R) antibody MT103 is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells, considered the most powerful "killer cells" of the human immune system, to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. MT110 is the second BiTE antibody in clinical trials, and is being developed by Micromet in a phase 1 clinical trial for the treatment of patients with lung or gastrointestinal cancer. The third clinical stage antibody is adecatumumab, also known as MT201, a human monoclonal antibody which targets epithelial cell adhesion molecule (EpCAM)-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The fourth clinical stage antibody is MT293 which is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer. Th
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
2. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
3. Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
4. ESBATechs Lead Antibody Fragment Enters Clinical Development for Ophthalmic Indications
5. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
6. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
7. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
8. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
11. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 2Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 3Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 4Masimo Receives 2009 Zenith Award at the American Association of Respiratory Care Congress 5Confusion Over Homeopathic Medicines in Alexa Ray Joel's Hospitalization Clarified by the American Association of Homeopathic Pharmacists (AAHP) 2St. Luke's Hospital Acquires Pioneering Technology From BrainLAB 2St. Luke's Hospital Acquires Pioneering Technology From BrainLAB 3Platelet Rich Plasma Therapy 28PRP 29 Accelerates Healing of Joint Injuries Osteoarthritis Pain 49564 1Platelet Rich Plasma Therapy 28PRP 29 Accelerates Healing of Joint Injuries Osteoarthritis Pain 49564 2Platelet Rich Plasma Therapy 28PRP 29 Accelerates Healing of Joint Injuries Osteoarthritis Pain 49564 3Platelet Rich Plasma Therapy 28PRP 29 Accelerates Healing of Joint Injuries Osteoarthritis Pain 49564 4Responses After Completion of Therapy Increase Pixantrone Complete Remission 28CR 29 Unconfirmed Complete Remission 28CRu 29 Rate to 24 25 and Overa 4621 1Responses After Completion of Therapy Increase Pixantrone Complete Remission 28CR 29 Unconfirmed Complete Remission 28CRu 29 Rate to 24 25 and Overa 4621 2Responses After Completion of Therapy Increase Pixantrone Complete Remission 28CR 29 Unconfirmed Complete Remission 28CRu 29 Rate to 24 25 and Overa 4621 3Responses After Completion of Therapy Increase Pixantrone Complete Remission 28CR 29 Unconfirmed Complete Remission 28CRu 29 Rate to 24 25 and Overa 4621 4Responses After Completion of Therapy Increase Pixantrone Complete Remission 28CR 29 Unconfirmed Complete Remission 28CRu 29 Rate to 24 25 and Overa 4621 5Responses After Completion of Therapy Increase Pixantrone Complete Remission 28CR 29 Unconfirmed Complete Remission 28CRu 29 Rate to 24 25 and Overa 4621 6Study finds cancer is the second most frequent cause of death in individuals with schizophrenia 49558 1Study finds cancer is the second most frequent cause of death in individuals with schizophrenia 49558 2